TITLE

Therapeutic Moisturizers as Adjuvant Therapy for Psoriasis Patients

AUTHOR(S)
Gelmetti, Carlo
PUB. DATE
January 2009
SOURCE
American Journal of Clinical Dermatology;2009 Supplement, Vol. 10 Issue S1, p7
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
At any point in time, psoriasis affects 2-3% of the world's population and has one of the biggest impacts on quality of life of any dermatological disorder. Treatment is extremely costly and prevention of disease progression in severity and extent is crucial. Psoriasis treatment should include skin hydration (regular use of moisturizers and emollients), careful, gentle skin cleansing, and identification and avoidance of Koebner phenomenon triggers (excoriation, maceration) and infectious foci (Streptococcus pyogenes). Moisturizers have been shown to significantly improve skin conditions and quality of life for psoriasis patients. They are a valuable first-line treatment, as dry skin is common and adds to the irritability of the diseased skin. Most patients respond well to topical treatment with topical corticosteroids, emollients, coal tar, anthralin (dithranol) or calcipotriol. Emollients are the most prescribed products, providing transient relief from irritation and some possessing antiinflammatory properties. Moisturizers and emollients should be used in the following cases: minimal psoriasis, napkin psoriasis, psoriasis of the folds, psoriatic skin damaged by previous local treatments, and in pregnancy or women of childbearing age.
ACCESSION #
44232597

 

Related Articles

  • DERMATOLOGICAL DISORDERS.  // Monthly Prescribing Reference;Feb2011, Vol. 27 Issue 2, p122 

    A part of the book "Monthly Prescribing Reference" for February 2011 is presented. It offers an overview of pharmacological treatments for dermatological disorders including acne, psoriasis and skin infections. The drugs include Aczone from Allergan, Neoral from Novartis and Abreva from...

  • A Two-Compound Product Containing Calcipotriol and Betamethasone Dipropionate Provides Rapid, Effective Treatment of Psoriasis vulgaris regardless of Baseline Disease Severity. van de Kerkhof, P. C. M.; Wasel, N.; Kragballe, K.; Cambazard, F.; Murray, S. // Dermatology (10188665);2005, Vol. 210 Issue 4, p294 

    Background: A two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet®/Dovobet®) has been evaluated in a large clinical trial programme, providing a wealth of data on the treatment of psoriasis vulgaris. Objective: To determine the effectiveness of the...

  • Therapy explosion. SCHWANKE, JANE // Dermatology Times;Aug2005, Vol. 26 Issue 8, p28 

    The article suggests various therapies used in the treatment of psoriasis. The various procedures used includes T-cell drugs Raptiva(efalizumab, Biogen), the best therpy for treating psoriasis, granuloma annulare, lichenplanus, alopecia areata and atopic dermatitis. The article also discourses...

  • Can-Fite: therapeutic approach bolstered by positive results in psoriasis trial.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p18 

    The article reports on the positive outcome of the psoriasis trial of Israel-based biopharmaceutical firm Can-Fite Biopharma Ltd. The 75-patient Phase II double-blind clinical study of the anti-TNF drug CF101 in patients with moderate to severe psoriasis resulted to efficacy upon oral...

  • Offer systemic therapy as first-line defense. Rutledge, Barbara J. // Dermatology Times;Sep2005 Supplement 4, Vol. 25, pS16 

    Evaluates the efficacy of alefacept therapy as first-line defense for psoriasis. Impact of psoriasis on the quality of life of the patient; Number of people affected with the disease of the year; Treatment paradigms for psoriasis.

  • Some Observations on Reporting Quality of Life in Treatment of Psoriasis in Outpatient Clinics. Lindberg, Magnus; Berg, Mats // Acta Dermato-Venereologica;2013, Vol. 93 Issue 2, p210 

    The article discusses a study on whether the Dermatology Life Quality Index (DLQI) and/or the visual analogue scale (VAS) could be recommended for use in everyday practice for treatment follow-ups in psoriasis in Swedish outpatient clinics. The DLQI is described as a quality of life instrument...

  • Clinical audit: baseline Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) assessment of psoriasis patients. Dilnawaz, Mansoor; Sadiq, Sakina; Zafar Iqbal Shaikh; Aziz, Humera; Saima Ali Khan; Jawad, Beenish // Journal of Pakistan Association of Dermatologists;Oct-Dec2013, Vol. 23 Issue 4, p407 

    Objective To assess the combined effect of PASI and DLQI on the overall care and treatment plan. Patients and methods 30 patients of psoriasis were included from the dermatology ward and the out-patients. The method of data collection was prospective. The basis of proposal was our local...

  • Adalimumab in it for the long haul in psoriasis.  // PharmacoEconomics & Outcomes News;3/26/2005, Issue 474, p17 

    Discusses research being done on the effectiveness of adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis among patients in the U.S. Reference to studies by several researchers published in the March 2005 issue of the "Journal of the American Academy of Dermatology";...

  • Evaluation of efalizumab using safe psoriasis control. Papp, Kim A.; Henninger, Eric // BMC Dermatology;2006, Vol. 6, p8 

    Background: Safe Psoriasis Control (SPC) is an important comprehensive measure that is validated for the assessment of benefit:risk of psoriasis treatments, combining efficacy, quality of life, and safety measures. The objective of this analysis was to assess the benefit:risk of efalizumab, a...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics